Indian drugs company urges data exclusivity review;

Abstract

One of India's biggest drugs companies is urging the government to change the rules on data exclusivity, saying the country needs to balance the interests of multinational pharmaceutical companies and India's home-grown drugs industry. Representatives from Nicholas Piramal told the government last month that India should grant 5 years of protection for test data submitted to the government during an application for approval of a new drug.